Shattuck Labs, Inc. (STTK)

NASDAQ: STTK · Real-Time Price · USD
0.7743
-0.0497 (-6.03%)
Jul 10, 2025, 4:00 PM - Market closed
-6.03%
Market Cap 37.09M
Revenue (ttm) 4.61M
Net Income (ttm) -70.61M
Shares Out 47.90M
EPS (ttm) -1.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 232,579
Open 0.8042
Previous Close 0.8240
Day's Range 0.7501 - 0.8468
52-Week Range 0.6922 - 4.9900
Beta 1.64
Analysts Hold
Price Target 3.00 (+287.45%)
Earnings Date Jul 31, 2025

About STTK

Shattuck Labs, Inc., a biotechnology company, develops antibodies for the treatment of inflammatory and immune-mediated diseases. The company’s lead product candidate includes SL-325, a DR3 blocking monoclonal antibody, which activates immune responses through binding a single receptor, DR3; and SL-425. It also develops multiple preclinical DR3-based bispecific antibodies for the treatment of inflammatory bowel disease; and a series of bispecific antibodies targeting DR3 and other clinically validated targets. In addition, the company is involv... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Oct 9, 2020
Employees 44
Stock Exchange NASDAQ
Ticker Symbol STTK
Full Company Profile

Financial Performance

In 2024, Shattuck Labs's revenue was $5.72 million, an increase of 245.26% compared to the previous year's $1.66 million. Losses were -$75.41 million, -13.62% less than in 2023.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for STTK stock is "Hold." The 12-month stock price target is $3.0, which is an increase of 287.45% from the latest price.

Price Target
$3.0
(287.45% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Shattuck Labs Announces Participation in Upcoming Leerink Partners Therapeutics Forum: I&I and Metabolism

AUSTIN, TX and DURHAM, NC, July 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec...

8 days ago - GlobeNewsWire

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

– Company advances SL-325 program with an IND filing expected in the third quarter of 2025 – – Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027 –...

2 months ago - GlobeNewsWire

Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor ne...

3 months ago - GlobeNewsWire

Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

– Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-cla...

3 months ago - GlobeNewsWire

Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

– SL-325 is a high-affinity DR3 blocking antibody being developed for the treatment of inflammatory bowel disease (IBD); No evidence of toxicity or residual agonism observed in non-human primate toxic...

5 months ago - GlobeNewsWire

Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

AUSTIN, TX & DURHAM, NC, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necro...

5 months ago - GlobeNewsWire

Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress

AUSTIN, TX and DURHAM, NC, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec...

5 months ago - GlobeNewsWire

Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

AUSTIN, TX and DURHAM, NC, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec...

6 months ago - GlobeNewsWire

Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025

AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor nec...

6 months ago - GlobeNewsWire

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

9 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Shareholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESSWIRE / October 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ...

9 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Shareholders to Connect

NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

9 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESSWIRE / October 23, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

9 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 22, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

9 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

9 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Is Investigating Shattuck Labs, Inc. (STTK) And Encourages Stockholders to Connect

NEW YORK CITY, NY / ACCESSWIRE / October 20, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

9 months ago - Accesswire

Shattuck Labs, Inc. (STTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

9 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Shattuck Labs, Inc. (STTK) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

9 months ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (N...

9 months ago - Accesswire

Shattuck Labs' stock craters as biotech scraps main product candidate after failed trial

The stock hit a low of $1.37 earlier in the session, matching its record closing low that was set in October 2023.

10 months ago - Market Watch

Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway

– Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvem...

10 months ago - GlobeNewsWire

Shattuck Labs Announces Participation in Upcoming BTIG Virtual Biotechnology Conference

AUSTIN, TX and DURHAM, NC, July 30, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion pr...

1 year ago - GlobeNewsWire

Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes

AUSTIN, TX & DURHAM, NC, July 01, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion prote...

1 year ago - GlobeNewsWire

Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leuk

– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall...

1 year ago - GlobeNewsWire

Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML)

AUSTIN, TX and DURHAM, NC, June 10, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (Nasdaq: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion pro...

1 year ago - GlobeNewsWire